V8.0 版权所有© 2001-2026 渝B2-20050021-1
渝公网安备 50019002500403号违法和不良信息举报中心举报邮箱：jubao@cqvip.com
互联网出版许可证 新出网证(渝)字10号机构客服热线 023-67882612
- Expert consensus on the detection and clinical application of tumor mutational burden 认领 引用
- 1
- 作者 Zhenying Guo Chunwei Xu +168 位作者 Shirong Zhang Yue Hao Xiaotong Hu Ming Zhao Chan Xiang Yingshi Piao Pingli Sun Xueping Xiang Jing Zhao Huanwen Wu Weixing Li Jinpu Yu Jingping Yuan Shuangshuang Wang Cong Wang Yun Gu Bingjian Lv Liping Zhang Yueping Liu Xiaobin Cui Weizhong Gu Yining Li Wei Wang Wenjun Yang Weiguo Long Jingjing Xiang Hong Mou Biao Liu Huajuan Ruan Yubin Wang Yongjie Zhu Feng Wang Zhonghua Wang Xiaomin Feng Xing Liu Peng Li Min Deng Bin Lian Lili Mao Qian Wang Wenxian Wang Zhengbo Song Ziming Li Wenzhao Zhong Zhijie Wang Shengxiang Ren Wenfeng Fang Yongchang Zhang Jingjing Liu Xiuyu Cai Anwen Liu Wen Li Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Yu Chen Yu Zhang Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Peng Shen Xiaoyan Li Chuanhao Tang Chengzhi Zhou Junping Zhang Junli Xue Hui Guo Qian Chu Rui Meng Jingxun Wu Rui Zhang Jin Zhou Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Yuanyuan Lu Xiaofeng Chen Rui Ge Enyong Dai Yu Han Jian Zhang Yinghua Ji Xianbin Liang Hongmei Zhang Xuelei Ma Xuewen Liu Yu Yao Peng Luo Weiwei Pan Fei Pang Fan Wu Dejian Gu Li Wang Liping Wang Youcai Zhu Li Lin Weiwen Li Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Yinbin Zhang Binbin Song Wenfeng Li Jianfei Fu Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Qing Ji Yuan Fang Qing Wei Zhen Wang Bin Wan Donglai Lv Xiaofeng Li Shengjie Yang Jing Kang Jiatao Zhang Chao Zhang Lin Shi Yina Wang Bihui Li Zhang Zhang Ke Wang Zhefeng Liu Nong Yang Lin Wu Xiaobing Chen Gu Jin Zhongwu Li Miao Li Guansong Wang Jiandong Wang Meiyu Fang Yong Fang Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Biyun Wang Lu Si Yong Song Yuanzhi Lu Aijun Liu Yuchen Han 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第2期218-246,共29页
- As an emerging biomarker,tumor mutational burden(TMB)has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy.Currently,TMB is detected primarily by whole-exome sequencing o... As an emerging biomarker,tumor mutational burden(TMB)has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy.Currently,TMB is detected primarily by whole-exome sequencing or targeted panel sequencing on high-throughput sequencing platforms.However,the lack of uniformity in detection methods,threshold settings,and reporting formats,as well as the significant differences in TMB values among different cancer types,have hindered the standardized application of this biomarker in clinical practice.This consensus focuses on the definition,standardization of detection,clinical significance,and limitations of TMB,and provides consensus recommendations for the clinical application of TMB in real-world practice in China.This consensus is aimed at helping clinicians and laboratory personnel understand the clinical significance and testing standards of TMB,promoting more accurate interpretation of test results,and improving patient care. 展开更多
- 关键词 Biomarkers tumor mutational burden tumor immunotherapy targeted panel sequencing whole-exome sequencing
- Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration 认领 引用 被引量：1
- 2
- 作者 Huijing Feng Yang Xia +106 位作者 Wenxian Wang Chunwei Xu Qian Wang Zhengbo Song Ziming Li Jinpu Yu Wenzhao Zhong Zhijie Wang Yongchang Zhang Jingjing Liu Shirong Zhang Xiuyu Cai Anwen Liu Wen Li Ping Zhan Hongbing Liu Tangfeng Lyu Liyun Miao Lingfeng Min Gen Lin Long Huang Jingping Yuan Zhansheng Jiang Xingxiang Pu Chuangzhou Rao DongqingLyu Zongyang Yu Xiaoyan Li Chuanhao Tang Chengzhi Zhou Qi Mei Hui Guo Qian Chu Rui Meng Xuewen Liu Jingxun Wu Jin Zhou Zhengfei Zhu Weiwei Pan Fei Pang Meizhen Hu Kai Wang Fan Wu Bingwei Xu Ling Xu Liping Wang Youcai Zhu Jisheng Li Yanru Xie Xinqing Lin Jing Cai Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Jing Kang Jiatao Zhang Chao Zhang Wenbin Gao Jianhui Huang Yinbin Zhang Pingli Sun Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Yue Hao Zheng Wang Bing Wan Donglai Lyu Xiaodong Jiao Lin Shi Gang Lan Shengjie Yang Yanhong Shang Yina Wang Bihui Li Gang Jin Kang Zheng Jun Ma Wenfeng Li Zhang Zhang Zhongwu Li Yuan Li Zhefeng Liu Xuelei Ma Nong Yang Lin Wu Qiming Wang Guansong Wang Zhuan Hong Jiandong Wang Meiyu Fang Yong Fang Xixu Zhu Yi Shen Ke Wang Xiubao Ren Yiping Zhang Shenglin Ma Junping Zhang Yong Song Wenfeng Fang Yuanzhi Lu 《Cancer Biology & Medicine》 SCIE CAS CSCD 2025年第3期237-265,共29页
- Alterations in the mesenchymal-epithelial transition factor(MET)gene are critical drivers of non-small cell lung cancer(NSCLC).In recent years advances in precision therapies targeting MET alterations have significant... Alterations in the mesenchymal-epithelial transition factor(MET)gene are critical drivers of non-small cell lung cancer(NSCLC).In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients.These alterations include MET exon 14 skipping mutations(MET exon 14 skipping),MET gene amplifications,MET point mutations(primarily kinase domain mutations),and MET protein overexpression.Accurate identification of these alterations and appropriate selection of patient populations and targeted therapies are essential for improving clinical outcomes.The East China Lung Cancer Group,Youth Committee(ECLUNG YOUNG,Yangtze River Delta Lung Cancer Cooperation Group)has synthesized insights from China’s innovative drug development landscape and clinical practice to formulate an expert consensus on the diagnosis and treatment of NSCLC patients with MET alterations.This consensus addresses key areas,such as optimal testing timing,testing methods,testing strategies,quality control measures,and treatment approaches.By offering standardized recommendations,this guidance aims to streamline diagnostic and therapeutic processes and enhance clinical decision-making for NSCLC with MET alterations. 展开更多
- 关键词 Mesenchymal-epithelial transition factor MET exon 14 skipping mutation MET amplification non-small cell lung cancer precision medicine targeted therapy tyrosine kinase
- The clinical effects of DC-CIK cells combined with chemotherapy in the treatment of advanced NSCLC 认领 引用 被引量：13
- 3
- 作者 Junping Zhang Guanghua Mao +8 位作者 Yaping Han Xiaoling Yang Huijing Feng Linzi Jia Ting Zhi Yan Xiao Libin Zhang Jiangtao Wang Tianliang Shi 《The Chinese-German Journal of Clinical Oncology》 2012年第2期67-71,共5页
- Objective: The aim of the study was to evaluate the safety and therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with chemotherapy in advanced non-small... Objective: The aim of the study was to evaluate the safety and therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Methods: Fifty patients with advanced NSCLC (stages III to IV), who had received therapies in our Center (Department of Biotherapy, Affiliated to Cancer Hospital of Shanxi Medical University, Taiyuan, China) from August 2008 to January 2010, were treated by DC-CIK + chemotherapy as the combined treatment group; fifty advanced NSCLC patients treated with chemotherapy at the same time served as controls. The immunologic function, short-term therapeutic effects, the 1-year survival rate, the life quality, the chemotherapy side effects were compared between the two groups, the safety and therapeutic effects of DC-CIK cells therapy were observed too. Results: There was no obvious change of subsets of T cells in peripheral blood before and after therapy in DC-CIK + chemotherapy group, and IFN-γ was improved after therapy in this group (P < 0.05); in chemotherapy alone group, the ratios of CD3+CD4+, CD3+CD8+, CD3-CD56+ cells and the secretion of IL-2, TNF-α decreased significantly after therapy (P < 0.05); the ratios of CD3+CD8+, CD3+CD56+ were improved after cell culture (P < 0.05). The disease control rate (DCR) of DC-CIK + chemotherapy group was higher than that in the chemotherapy alone group (78.0% vs 56.0%, P < 0.05); the 1-year survival rates of DC-CIK + chemotherapy group and chemotherapy alone group were 50% and 44% respectively, had no significant difference. Compared with chemotherapy alone group, the occurrence of chemotherapy side effects (including bone marrow suppression, nausea and vomiting, peripheral nerve toxicity) was less in the DC-CIK + chemotherapy group (P < 0.05). The physical and appetite were better in DC-CIK + chemotherapy group after therapy. Conclusion: To compare with simple chemotherapy, DC-CIK + chemotherapy for advanced NSCLC is safe and effective, and it can improve patients' life quality and remission rate, and prolong their survival time. 展开更多
- 关键词 autologous dendritic cells co-cultured with cytokine-induced killer cells （DC-CIK） non-small cell lung cancer （NSCLC） adoptive cellular immunotherapy chemotherapy
- 恶性肿瘤患者基于临床和血液学标记物的免疫检查点抑制剂相关不良事件预测模型的建立 认领 引用 被引量：5
- 4
- 作者 许辉茹 冯慧晶 +1 位作者 任秀宝 张俊萍 《中国肿瘤临床》 CAS CSCD 北大核心 2022年第12期595-606,共12页
- 目的:本研究的目的是建立基于临床和血液学参数的免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗的恶性肿瘤患者的免疫相关不良事件(immune-related adverse effects,irAEs)预测模型,如果经过验证,这些标记物的优点是易于整... 目的:本研究的目的是建立基于临床和血液学参数的免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗的恶性肿瘤患者的免疫相关不良事件(immune-related adverse effects,irAEs)预测模型,如果经过验证,这些标记物的优点是易于整合到临床使用中,成本低廉。方法:本研究是对2016年1月到2020年12月在天津医科大学肿瘤医院和山西白求恩医院接受至少一剂ICIs治疗的恶性肿瘤患者的回顾性研究。收集了基线特征、治疗细节和不良事件的数据。采用t检验、χ2检验和Logistic回归等方法确定影响因素,建立预测模型。结果:任何级别和3级及以上的irAEs发生率分别为16.03%(76/474)和2.32%(11/474),其中最常见的分别为内分泌毒性37.1%(39/105)和肺炎7.6%(8/105)。多因素分析显示,2线治疗irAEs发生的风险更大[比值比(Odds Ratio,OR)=3.302];球蛋白(OR=1.086)与irAEs的发生呈正相关,而直接胆红素(direct bilirubin,DBIL)(OR=0.723)与其呈负相关(P<0.05)。最终建立了基于“ICIs类型、治疗线数、球蛋白、DBIL和淋巴细胞/单核细胞比值(lymphocyte to monocyte ratio,LMR)”的预测模型,其受试者工作特征(receiver operating characteristic,ROC)曲线下面积(area under the curve,AUC)为0.775,95%CI:0.711~0.840,P<0.05,临界值为0.118,敏感度为92.5%,特异度为56.6%。结论:基于ICIs类型、治疗线数、球蛋白、DBIL和LMR的预测模型对单纯接受ICIs的恶性肿瘤患者的irAEs预测效果较好,其中治疗线数、球蛋白和DBIL是irAEs发生的独立预测因素。ICIs作为2线治疗以及治疗前高球蛋白和低DBIL的人群发生ir-AEs的风险较高。 展开更多
- 关键词 免疫检查点抑制剂 免疫相关不良事件 标志物 预测模型
- International guidelines on the diagnosis and treatment of NUT carcinoma 认领 引用 被引量：2
- 5
- 作者 Yu Zhang Qi Zhang +171 位作者 Yue Hao Jia Luo Yingshi Piao Wenxian Wang Zhengbo Song Ziming Li Luka Brcic Aijun Liu Jinpu Yu Yasuhiro Tsutani Wenzhao Zhong Wenfeng Fang Zhijie Wang Shengxiang Ren Athanasios G.Papavassiliou Yongchang Zhang Jingjing Liu Shirong Zhang Xiuyu Cai Ayten Kayi Cangir Anwen Liu Wen Li Filippo Lococo Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Helmut Popper Yu Chen Jingping Yuan Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Kalevi Kairemo Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Ashrafian Leanne Xiaoyan Li Chuanhao Tang Hifzur R.Siddique Chengzhi Zhou Junping Zhang Junli Xue Vishal Shelat Hui Guo Qian Chu Rui Meng Fatemeh Ardeshir Jingxun Wu Rui Zhang Jin Zhou Robert A.Kratzke Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Fiorella Calabrese Yang Xia Alessandro Wasum Mariani Yuanyuan Lu Xiaofeng Chen Mark A.Klein Rui Ge Enyong Dai Axel H.Schönthal Yu Han Zhenying Guo Jian Zhang Yinghua Ji Xianbin Liang Hongmei Zhang Xuelei Ma Marco Chiappetta Xuewen Liu Francoise Galateau Salle Yu Yao Malgorzata Szolkowska Weiwei Pan Fei Pang Fan Wu Stefan B.Watzka Liping Wang Youcai Zhu Li Lin Aparna Sharma Jianfei Tu Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Marjorie G.Zauderer Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Elizabeth Dudnik Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Jianhui Huang Yue Feng Yinbin Zhang Binbin Song Wenfeng Li Jianfei Fu Marina K.Baine Pingli Sun Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Jing Wu Yunyun Yang Yuan Fang Zhen Wang Bin Wan Donglai Lv Huafei Chen Shengjie Yang Jing Kang Jiatao Zhang Chao Zhang Lin Shi Yina Wang Mohamed Emam Sobeih Bihui Li Bin Lian Lili Mao Zhang Zhang Ke Wang Zhongwu Li Zhefeng Liu Nong Yang Lin Wu Xiaobing Chen Gu Jin Miao Li Guansong Wang Thomas U.Marron Jiandong Wang Sanjay Popat Meiyu Fang Yong Fang Daniel Mansilla Yuan Li Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Aaron S.Mansfield Biyun Wang Lu Si Anja C.Roden Bjørn H.Grønberg Yong Song Geoffrey I.Shapiro Christopher A.French Yuanzhi Lu Qian Wang Chunwei Xu 《The Innovation》 EI 2026年第1期111-126,共16页
- 1(NUTM1)gene rearrangements(15q14).In 1991,two independent research teams reported NC cases characterized by the t(15;19)translo-cation.1,2 In vitro studies by French et al.3 led to the pivotal discovery of NC in 2003... 1(NUTM1)gene rearrangements(15q14).In 1991,two independent research teams reported NC cases characterized by the t(15;19)translo-cation.1,2 In vitro studies by French et al.3 led to the pivotal discovery of NC in 2003 as a distinct disease entity driven by the fusion of bromodo-main and extraterminal domain(BET)protein 4(BRD4)and NUTM1.In 2004,the World Health Organization(WHO)classified tumors with t(15;19)translocation as a thymic malignancy and designated it“NUT midline carcinoma,”due to its predominant occurrence in midline organs.4 However,subsequent reports revealed NC’s emergence in numerous nonmidline organs,leading to its reclassification as the independent entity“NUT carcinoma of the thorax”by the WHO in 2015.5 NC exhibits rapid progression and profound resistance to conventional radiotherapy and chemotherapy. 展开更多
- 关键词 t BRD vitro studies translocation nut carcinoma thorax thymic malignancy nut midline carcinoma NUTM
-
- Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations 认领 引用 被引量：6
- 6
- 作者 Wenxian Wang Bin Lian +133 位作者 Chunwei Xu Qian Wang Ziming Li Nan Zheng Aijun Liu Jinpu Yu Wenzhao Zhong Zhijie Wang Yongchang Zhang Jingjing Liu Shirong Zhang Xiuyu Cai Anwen Liu Wen Li Lili Mao Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Yu Chen Jingping Yuan Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Xiaoyan Li Chuanhao Tang Chengzhi Zhou Junping Zhang Junli Xue Hui Guo Qian Chu Rui Meng Xuewen Liu Jingxun Wu Rui Zhang Jin Zhou Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Yuanyuan Lu Xiaofeng Chen Jian Feng Rui Ge Enyong Dai Yu Han Weiwei Pan Fei Pang Xin Huang Meizhen Hu Qing Hao Kai Wang Fan Wu Binbin Song Bingwei Xu Liping Wang Youcai Zhu Li Lin Yanru Xie Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Jianhui Huang Yue Feng Yinbin Zhang Pingli Sun Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Yue Hao Zhen Wang Bin Wan Donglai Lv Shengjie Yang Jin Kang Jiatao Zhang Chao Zhang Wenfeng Li Jianfei Fu Lizhi Wu Shijie Lan Juanjuan Ou Lin Shi Zhanqiang Zhai Yina Wang Bihui Li Zhang Zhang Ke Wang Xuelei Ma Zhongwu Li Zhefeng Liu Nong Yang Lin Wu Huijuan Wang Gu Jin Guansong Wang Jiandong Wang Hubing Shi Meiyu Fang Yong Fang Yuan Li Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Biyun Wang Yong Song Zhengbo Song Wenfeng Fang Yuanzhi Lu Lu Si 《The Innovation》 EI 2024年第6期100-116,共17页
- The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and survival.When the BRAF gene mutates,it can lead to abnormal activation of the signa... The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and survival.When the BRAF gene mutates,it can lead to abnormal activation of the signaling pathway,which promotes cell proliferation,inhibits cell apoptosis,and ultimately contributes to the occurrence and development of cancer.BRAF mutations are widely present in various cancers,including malignant melanoma,thyroid cancer,colorectal cancer,non-small cell lung cancer,and hairy cell leukemia,among others.BRAF is an important target for the treatment of various solid tumors,and targeted combination therapies,represented by BRAF inhibitors,have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors. 展开更多
- 关键词 BRAF diagnosis treatment
-
- 题名Expert consensus on the detection and clinical application of tumor mutational burden 认领 引用
- 1
- 作者 Zhenying Guo Chunwei Xu Shirong Zhang Yue Hao Xiaotong Hu Ming Zhao Chan Xiang Yingshi Piao Pingli Sun Xueping Xiang Jing Zhao Huanwen Wu Weixing Li Jinpu Yu Jingping Yuan Shuangshuang Wang Cong Wang Yun Gu Bingjian Lv Liping Zhang Yueping Liu Xiaobin Cui Weizhong Gu Yining Li Wei Wang Wenjun Yang Weiguo Long Jingjing Xiang Hong Mou Biao Liu Huajuan Ruan Yubin Wang Yongjie Zhu Feng Wang Zhonghua Wang Xiaomin Feng Xing Liu Peng Li Min Deng Bin Lian Lili Mao Qian Wang Wenxian Wang Zhengbo Song Ziming Li Wenzhao Zhong Zhijie Wang Shengxiang Ren Wenfeng Fang Yongchang Zhang Jingjing Liu Xiuyu Cai Anwen Liu Wen Li Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Yu Chen Yu Zhang Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Peng Shen Xiaoyan Li Chuanhao Tang Chengzhi Zhou Junping Zhang Junli Xue Hui Guo Qian Chu Rui Meng Jingxun Wu Rui Zhang Jin Zhou Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Yuanyuan Lu Xiaofeng Chen Rui Ge Enyong Dai Yu Han Jian Zhang Yinghua Ji Xianbin Liang Hongmei Zhang Xuelei Ma Xuewen Liu Yu Yao Peng Luo Weiwei Pan Fei Pang Fan Wu Dejian Gu Li Wang Liping Wang Youcai Zhu Li Lin Weiwen Li Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Yinbin Zhang Binbin Song Wenfeng Li Jianfei Fu Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Qing Ji Yuan Fang Qing Wei Zhen Wang Bin Wan Donglai Lv Xiaofeng Li Shengjie Yang Jing Kang Jiatao Zhang Chao Zhang Lin Shi Yina Wang Bihui Li Zhang Zhang Ke Wang Zhefeng Liu Nong Yang Lin Wu Xiaobing Chen Gu Jin Zhongwu Li Miao Li Guansong Wang Jiandong Wang Meiyu Fang Yong Fang Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Biyun Wang Lu Si Yong Song Yuanzhi Lu Aijun Liu Yuchen Han
- 机构 Cancer Center,Department of Pathology,Zhejiang Provincial People’s Hospital（Affiliated People’s Hospital）,Hangzhou Medical College Hangzhou Institute of Medicine（HIM）,Chinese Academy of Sciences Translational Medicine Research Center,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou First People’s Hospital,Cancer Center,Westlake University School of Medicine Department of Chemotherapy,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Department of Pathology,Sir Run Run Shaw Hospital,Zhejiang University Ningbo Clinical Pathology Diagnosis Center Department of Pathology,Shanghai Chest Hospital,Shanghai Jiao Tong University Department of Pathology,Beijing Tongren Hospital,Capital Medical University Department of Pathology,The Second Hospital of Jilin University Department of Pathology,The Second Affiliated Hospital,School of Medicine,Zhejiang University Department of Pathology,The First Affiliated Hospital,College of Medicine,Zhejiang University Department of Pathology,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College Laboratory Medicine Center,Zhejiang Center for Clinical Laboratory,Zhejiang Provincial People’s Hospital,Affiliated People’s Hospital,Hangzhou Medical College Department of Cancer Molecular Diagnostics Core,Tianjin Medical University Cancer Institute and Hospital Department of Pathology,Renmin Hospital of Wuhan University Department of Pathology,Affiliated Hospital of Nanjing University of Chinese Medicine,Jiangsu Province Hospital of Chinese Medicine Department of Pathology,The First Affiliated Hospital of Nanjing Medical University（Jiangsu Province Hospital） Department of Pathology,Women’s Hospital of Nanjing Medical University,Nanjing Women and Children’s Healthcare Hospital Department of Surgical Pathology Women’s Hospital,School of Medicine,Zhejiang University Department of Pathology,Shanghai Pudong Hospital,School of Medicine,Fudan University Department of Pathology,The Fourth Hospital of Hebei Medical University Department of Pathology,Nanjing Drum Tower Hospital,Nanjing University Department of Pathology,Children’s Hospital Zhejiang University School of Medicine Department of Pathology,Stomatology Hospital,School of Stomatology,Zhejiang University Department of Pathology,Tongde Hospital of Zhejiang Province Department of Pathology,Affiliated Hospital of Hangzhou Normal University Department of Pathology,The People’s Hospital of Leshan Department of Pathology,Affiliated Hangzhou First People’s Hospital,Westlake University School of Medicine Department of Pathology,Chun’an First People’s Hospital Department of Pathology,The Affiliated Suzhou Hospital,Nanjing Medical University Department of Pathology,The First People’s Hospital of Hangzhou Lin’an District,Affiliated Lin’an People’s Hospital,Hangzhou Medical College Department of Pathology,Tiantai County People’s Hospital Department of Pathology,First People’s Hospital of Aksu Department of Pathology,Xianju People’s Hospital,Zhejiang Southeast Campus of Zhejiang Provincial People’s Hospital,Affiliated Xianju’s Hospital,Hangzhou Medical College Department of Pathology,Dinghai Branch of Zhejiang Provincial People’s Hospital Department of Pathology,Shulan（Hangzhou）Hospital Department of Pathology,The First Affiliated Hospital of Wenzhou Medical University Department of Pathology,Zhejiang Provincial People’s Hospital（Fuyang Campus） Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Melanoma and Sarcoma,Peking University Cancer Hospital&Institute Department of Respiratory Medicine,Affiliated Hospital of Nanjing University of Chinese Medicine,Jiangsu Province Hospital of Chinese Medicine Department of Shanghai Lung Cancer Center,Shanghai Chest Hospital,Shanghai Jiao Tong University Guangdong Lung Cancer Institute,Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,School of Medicine State Key Laboratory of Molecular Oncology,Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Department of Medical Oncology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine Department of Medical Oncology,Lung Cancer and Gastrointestinal Unit,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Thoracic Cancer,Jilin Cancer Hospital Department of VIP Inpatient,Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine Department of Oncology,Second Affiliated Hospital of Nanchang University Key Laboratory of Respiratory Disease of Zhejiang Province,Department of Respiratory and Critical Care Medicine,Second Affiliated Hospital of Zhejiang University School of Medicine,Cancer Center,Zhejiang University Department of Respiratory Medicine,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Affiliated Drum Tower Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Clinical Medical School of Yangzhou University,Subei People’s Hospital of Jiangsu Province Department of Medical Oncology,Fujian Medical University Cancer Hospital&Fujian Cancer Hospital Department of Oncology,Guizhou Provincial People’s Hospital Department of Internal Medicine,Cancer Center of PLA,Qinhuai Medical Area,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Integrative Oncology,Tianjin Medical University Cancer Institute and Hospital The Second Department of Thoracic Oncology,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Orthopedic Oncology Surgery,Beijing Ji shui tan Hospital,Peking University Department of Radiotherapy and Chemotherapy,Hwamei Hospital,University of Chinese Academy of Sciences Department of Pulmonary Medicine,Taizhou Hospital of Wenzhou Medical University Department of Respiratory Medicine,the 900th Hospital of the Joint Logistics Team（the Former Fuzhou General Hospital）,Fujian Medical University Department of Oncology,Nanfang Hospital,Southern Medical University Department of Oncology,Beijing Tiantan Hospital,Capital Medical University Department of Medical Oncology,Peking University International Hospital State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University Department of Thoracic Oncology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital Department of Oncology,Shanghai East Hospital,School of Medicine,Tongji University Department of Oncology,The Second Affiliated Hospital of Medical College,Xi’an Jiaotong University Department of Oncology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology Department of Medical Oncology,The First Affiliated Hospital of Medicine,Xiamen University Department of Medical Oncology,Cancer Hospital of China Medical University Department of Medical Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology Department of Radiation Oncology,Fudan University Shanghai Cancer Center Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Radiation Oncology,Peking University Cancer Hospital&Institute State Key Laboratory of Cancer Biology,National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases,Fourth Military Medical University Department of Oncology,Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital Department of General Surgery,Huadong Hospital Affiliated to Fudan University Department of Oncology and Hematology,China-Japan Union Hospital of Jilin University Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital Department of Oncology,Zhujiang Hospital,Southern Medical University Department of Oncology,The First Affiliated Hospital of Xinxiang Medical University Department of Oncology,The Third People’s Hospital of Zhengzhou Department of Biotherapy,State Key Laboratory of Biotherapy,Cancer Center,West China Hospital,Sichuan University Department of Oncology,the Third Xiangya Hospital,Central South University Department of Medical Oncology,The First Affiliated Hospital of Xi’an Jiaotong University Department of Cell Biology,College of Medicine,Jiaxing University Department of Medical,Shanghai OrigiMed Co Department of Medical,Menarini Silicon Biosystems SpA Department of Medical,Geneplus-Beijing Department of Oncology,Baotou Cancer Hospital Department of Thoracic Disease Diagnosis and Treatment Center,Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University Department of Oncology,Lishui Municipal Central Hospital Department of Interventional Pulmonary Diseases,Anhui Chest Hospital Department of Medical Oncology,Qilu Hospital,Cheeloo College of Medicine,Shandong University Department of Medical Oncology,Shanghai Changzheng Hospital,Naval Medical University Department of Oncology,Shandong Provincial Third Hospital,Cheeloo College of Medicine,Shandong University Department of The Comprehensive Cancer Center,Affiliated Drum Tower Hospital,Medical School of Nanjing University Department of Pathology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital Department of Oncology,The First Affiliated Hospital of Anhui Medical University Department of Interventional Oncology,The First Affiliated Hospital,Sun Yat-sen University Department of Respiratory Medicine,Huzhou Hospital,Zhejiang University School of Medicine Department of Medical Oncology,The Affiliated Hospital of Jiaxing University Department of Radiation Oncology,First Affiliated Hospital of Wenzhou Medical University Department of Medical Oncology,Affiliated Jinhua Hospital,Zhejiang University School of Medicine Senior Department of Oncology,The 5th Medical Center of PLA General Hospital Department of Pathology,Anhui Provincial Children’s Hospital Department of Radiation Oncology,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,The Affiliated Jiangning Hospital of Nanjing Medical University Department of Clinical Oncology,The 901 Hospital of Joint Logistics Support Force of People Liberation Army Department of Thoracic Surgery,Chuxiong Yi Autonomous Prefecture People’s Hospital Department of Respiratory Medicine,Zhongshan Hospital,Fudan University Department of Oncology,The First Affiliated Hospital,College of Medicine,Zhejiang University Department of Oncology,The Second Affiliated Hospital of Guilin Medical University International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education（MOE）,Guangzhou City Key Laboratory of Precision Chemical Drug Development,School of Pharmacy,Jinan University National Health Commission（NHC）Key Laboratory of Nuclear Medicine,Jiangsu Key Laboratory of Molecular Nuclear Medicine,Jiangsu Institute of Nuclear Medicine Department of Radiopharmaceuticals,School of Pharmacy,Nanjing Medical University Department of Oncology,The Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital Department of Bone and Soft-tissue Surgery,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Pathology,Peking University Cancer Hospital&Institute Department of Oncology,The Cancer Hospital of Qinghai Province Institute of Respiratory Diseases,Xinqiao Hospital,Third Military Medical University Department of Pathology,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Medical Oncology,Sir Run Run Shaw Hospital,Zhejiang University Department of Thoracic Surgery,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Oncology,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou Cancer Hospital,Cancer Center,Westlake University School of Medicine Department of Breast Cancer and Urological Medical Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University Department of Clinical Pathology,The First Affiliated Hospital of Jinan University Senior Department of Pathology,the 7th Medical Center of PLA General Hospital
- 出处 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第2期218-246,共29页
- 基金 supported by grants from the National Natural Science Foundation of China(Grant No.82072577) from the International Medical Association(Grant No.IMA-F-2025-001).
- 摘要 As an emerging biomarker,tumor mutational burden(TMB)has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy.Currently,TMB is detected primarily by whole-exome sequencing or targeted panel sequencing on high-throughput sequencing platforms.However,the lack of uniformity in detection methods,threshold settings,and reporting formats,as well as the significant differences in TMB values among different cancer types,have hindered the standardized application of this biomarker in clinical practice.This consensus focuses on the definition,standardization of detection,clinical significance,and limitations of TMB,and provides consensus recommendations for the clinical application of TMB in real-world practice in China.This consensus is aimed at helping clinicians and laboratory personnel understand the clinical significance and testing standards of TMB,promoting more accurate interpretation of test results,and improving patient care.
- 关键词 Biomarkers tumor mutational burden tumor immunotherapy targeted panel sequencing whole-exome sequencing
- 分类号 R730.4 [医药卫生—肿瘤]
- 题名Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration 认领 引用 被引量：1
- 2
- 作者 Huijing Feng Yang Xia Wenxian Wang Chunwei Xu Qian Wang Zhengbo Song Ziming Li Jinpu Yu Wenzhao Zhong Zhijie Wang Yongchang Zhang Jingjing Liu Shirong Zhang Xiuyu Cai Anwen Liu Wen Li Ping Zhan Hongbing Liu Tangfeng Lyu Liyun Miao Lingfeng Min Gen Lin Long Huang Jingping Yuan Zhansheng Jiang Xingxiang Pu Chuangzhou Rao DongqingLyu Zongyang Yu Xiaoyan Li Chuanhao Tang Chengzhi Zhou Qi Mei Hui Guo Qian Chu Rui Meng Xuewen Liu Jingxun Wu Jin Zhou Zhengfei Zhu Weiwei Pan Fei Pang Meizhen Hu Kai Wang Fan Wu Bingwei Xu Ling Xu Liping Wang Youcai Zhu Jisheng Li Yanru Xie Xinqing Lin Jing Cai Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Jing Kang Jiatao Zhang Chao Zhang Wenbin Gao Jianhui Huang Yinbin Zhang Pingli Sun Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Yue Hao Zheng Wang Bing Wan Donglai Lyu Xiaodong Jiao Lin Shi Gang Lan Shengjie Yang Yanhong Shang Yina Wang Bihui Li Gang Jin Kang Zheng Jun Ma Wenfeng Li Zhang Zhang Zhongwu Li Yuan Li Zhefeng Liu Xuelei Ma Nong Yang Lin Wu Qiming Wang Guansong Wang Zhuan Hong Jiandong Wang Meiyu Fang Yong Fang Xixu Zhu Yi Shen Ke Wang Xiubao Ren Yiping Zhang Shenglin Ma Junping Zhang Yong Song Wenfeng Fang Yuanzhi Lu
- 机构 Department of Thoracic Oncology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital Key Laboratory of Respiratory Disease of Zhejiang Province,Department of Respiratory and Critical Care Medicine,Second Affiliated Hospital of Zhejiang University School of Medicine,Cancer Center,Zhejiang University Department of Chemotherapy,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Institute of Cancer and Basic Medicine（ICBM）,Chinese Academy of Sciences Department of Respiratory Medicine,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Affiliated Hospital of Nanjing University of Chinese Medicine,Jiangsu Province Hospital of Chinese Medicine Department of Shanghai Lung Cancer Center,Shanghai Chest Hospital,Shanghai Jiao Tong University Department of Cancer Molecular Diagnostics Core,Tianjin Medical University Cancer Institute&Hospital Guangdong Lung Cancer Institute,Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,School of Medicine State Key Laboratory of Molecular Oncology,Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Department of Medical Oncology,Lung Cancer and Gastrointestinal Unit,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Thoracic Cancer,Jilin Cancer Hospital Translational Medicine Research Center,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou First People’s Hospital,Cancer Center,Zhejiang University School of Medicine Department of VIP Inpatient,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine Department of Oncology,Second Affiliated Hospital of Nanchang University Department of Respiratory Medicine,Affiliated Drum Tower Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Clinical Medical School of Yangzhou University,Subei People’s Hospital of Jiangsu Province Department of Medical Oncology,Fujian Medical University Cancer Hospital&Fujian Cancer Hospital Department of Pathology,Renmin Hospital of Wuhan University Department of Integrative Oncology,Tianjin Medical University Cancer Institute&Hospital Department of Medical Oncology,Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Radiotherapy and Chemotherapy,Hwamei Hospital,University of Chinese Academy of Sciences Department of Pulmonary Medicine,Taizhou Hospital of Wenzhou Medical University Department of Respiratory Medicine,the 900th Hospital of the Joint Logistics Team（the Former Fuzhou General Hospital）,Fujian Medical University Department of Oncology,Beijing Tiantan Hospital,Capital Medical University Department of Medical Oncology,Peking University International Hospital State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease/Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University Department of Medical Oncology,The First Affiliated Hospital of Xi’an Jiaotong University Department of Oncology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology Department of Oncology,the Third Xiangya Hospital,Central South University Department of Medical Oncology,the First Affiliated Hospital of Medicine,Xiamen University Department of Medical Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China Department of Radiation Oncology,Fudan University Shanghai Cancer Center Department of Cell Biology,College of Medicine,Jiaxing University Shanghai OrigiMed Co Menarini Silicon Biosystems SpA Department of Biotherapy,Cancer Institute,First Affiliated Hospital of China Medical University Department of Interventional Pulmonary Diseases,Anhui Chest Hospital Department of Oncology,Baotou Cancer Hospital Department of Thoracic Disease Diagnosis and Treatment Center,Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University Department of Medical Oncology,Qilu Hospital,Cheeloo College of Medicine,Shandong University Department of Oncology,Lishui Municipal Central Hospital Department of Pathology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital Department of Oncology,The First Affiliated Hospital of Anhui Medical University Department of Interventional Oncology,The First Affiliated Hospital,Sun Yat-sen University Department of Respiratory Medicine,Huzhou Hospital,Zhejiang University School of Medicine Department of Oncology,The Third Affiliated Hospital of Shenzhen University Department of Oncology,the Second Affiliated Hospital of Medical College,Xi’an Jiaotong University Department of Pathology,The Second Hospital of Jilin University Senior Department of Oncology,The 5th Medical Center of Chinese PLA General Hospital Department of Radiation Oncology,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,The Affiliated Jiangning Hospital of Nanjing Medical University Department of Clinical Oncology,The 901 Hospital of Joint Logistics Support Force of People Liberation Army Department of Medical Oncology,Shanghai Changzheng Hospital,Naval Medical University Department of Respiratory Medicine,Zhongshan Hospital,Fudan University Department of Thoracic Surgery,Chuxiong Yi Autonomous Prefecture People’s Hospital Department of Medical Oncology,Affiliated Hospital of Hebei University Department of Oncology,The First Affiliated Hospital,College of Medicine,Zhejiang University Department of Oncology,The Second Affiliated Hospital of Guilin Medical University Department of Oncology,The Second Hospital of Shanxi Medical University Department of Thoracic Surgery,Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University Department of Thoracic Surgery,Shanxi Provincial People’s Hospital/The Fifth Hospital of Shanxi Medical University/The Fifth Clinical Medical College of Shanxi Medical University Department of Radiation Oncology,First Affiliated Hospital of Wenzhou Medical College International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education（MOE）,Guangzhou City Key Laboratory of Precision Chemical Drug Development,School of Pharmacy,Jinan University Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Pathology,Peking University Cancer Hospital&Institute Department of Pathology,Fudan University Shanghai Cancer Center Department of Biotherapy,State Key Laboratory of Biotherapy,Cancer Center,West China Hospital,Sichuan University Department ofInternal Medicine,The Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital Institute of Respiratory Diseases,Xinqiao Hospital,Third Military Medical University Department of Medical Oncology,Jiangsu Cancer Hospital,Nanjing Medical University Affiliated Cancer Hospital Department of Pathology,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Medical Oncology,Sir Run Run Shaw Hospital,Zhejiang University Department of Thoracic Surgery,Affiliated Jinling Hospital,Medical School of Nanjing University National Health Commission（NHC）Key Laboratory of Nuclear Medicine,Jiangsu Key Laboratory of Molecular Nuclear Medicine,Jiangsu Institute of Nuclear Medicine Department of Radiopharmaceuticals,School of Pharmacy,Nanjing Medical University Department of Immunology,Tianjin Medical University Cancer Institute&Hospital Department of Oncology,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou Cancer Hospital,Cancer Center,Zhejiang University School of Medicine Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine Department of Clinical Pathology,The First Affiliated Hospital of Jinan University
- 出处 《Cancer Biology & Medicine》 SCIE CAS CSCD 2025年第3期237-265,共29页
- 摘要 Alterations in the mesenchymal-epithelial transition factor(MET)gene are critical drivers of non-small cell lung cancer(NSCLC).In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients.These alterations include MET exon 14 skipping mutations(MET exon 14 skipping),MET gene amplifications,MET point mutations(primarily kinase domain mutations),and MET protein overexpression.Accurate identification of these alterations and appropriate selection of patient populations and targeted therapies are essential for improving clinical outcomes.The East China Lung Cancer Group,Youth Committee(ECLUNG YOUNG,Yangtze River Delta Lung Cancer Cooperation Group)has synthesized insights from China’s innovative drug development landscape and clinical practice to formulate an expert consensus on the diagnosis and treatment of NSCLC patients with MET alterations.This consensus addresses key areas,such as optimal testing timing,testing methods,testing strategies,quality control measures,and treatment approaches.By offering standardized recommendations,this guidance aims to streamline diagnostic and therapeutic processes and enhance clinical decision-making for NSCLC with MET alterations.
- 关键词 Mesenchymal-epithelial transition factor MET exon 14 skipping mutation MET amplification non-small cell lung cancer precision medicine targeted therapy tyrosine kinase
- 分类号 R734.2 [医药卫生—肿瘤]
- 题名The clinical effects of DC-CIK cells combined with chemotherapy in the treatment of advanced NSCLC 认领 引用 被引量：13
- 3
- 作者 Junping Zhang Guanghua Mao Yaping Han Xiaoling Yang Huijing Feng Linzi Jia Ting Zhi Yan Xiao Libin Zhang Jiangtao Wang Tianliang Shi
- 机构 Department of Biotherapy,Affiliated to Cancer Hospital of Shanxi Medical University
- 出处 《The Chinese-German Journal of Clinical Oncology》 2012年第2期67-71,共5页
- 基金 Supported by a grant from the key Scientific Foundation of Shanxi Province (No. 051096-2)
- 摘要 Objective: The aim of the study was to evaluate the safety and therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Methods: Fifty patients with advanced NSCLC (stages III to IV), who had received therapies in our Center (Department of Biotherapy, Affiliated to Cancer Hospital of Shanxi Medical University, Taiyuan, China) from August 2008 to January 2010, were treated by DC-CIK + chemotherapy as the combined treatment group; fifty advanced NSCLC patients treated with chemotherapy at the same time served as controls. The immunologic function, short-term therapeutic effects, the 1-year survival rate, the life quality, the chemotherapy side effects were compared between the two groups, the safety and therapeutic effects of DC-CIK cells therapy were observed too. Results: There was no obvious change of subsets of T cells in peripheral blood before and after therapy in DC-CIK + chemotherapy group, and IFN-γ was improved after therapy in this group (P < 0.05); in chemotherapy alone group, the ratios of CD3+CD4+, CD3+CD8+, CD3-CD56+ cells and the secretion of IL-2, TNF-α decreased significantly after therapy (P < 0.05); the ratios of CD3+CD8+, CD3+CD56+ were improved after cell culture (P < 0.05). The disease control rate (DCR) of DC-CIK + chemotherapy group was higher than that in the chemotherapy alone group (78.0% vs 56.0%, P < 0.05); the 1-year survival rates of DC-CIK + chemotherapy group and chemotherapy alone group were 50% and 44% respectively, had no significant difference. Compared with chemotherapy alone group, the occurrence of chemotherapy side effects (including bone marrow suppression, nausea and vomiting, peripheral nerve toxicity) was less in the DC-CIK + chemotherapy group (P < 0.05). The physical and appetite were better in DC-CIK + chemotherapy group after therapy. Conclusion: To compare with simple chemotherapy, DC-CIK + chemotherapy for advanced NSCLC is safe and effective, and it can improve patients' life quality and remission rate, and prolong their survival time.
- 关键词 autologous dendritic cells co-cultured with cytokine-induced killer cells （DC-CIK） non-small cell lung cancer （NSCLC） adoptive cellular immunotherapy chemotherapy
- 分类号 R734.2 [医药卫生—肿瘤]
- 题名恶性肿瘤患者基于临床和血液学标记物的免疫检查点抑制剂相关不良事件预测模型的建立 认领 引用 被引量：5
- 4
- 作者 许辉茹 冯慧晶 任秀宝 张俊萍
- 机构 天津医科大学肿瘤医院生物技术研究室,国家恶性肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津市恶性肿瘤临床医学研究中心,天津市肿瘤免疫与生物治疗重点实验室 山西白求恩医院（山西医学科学院同济山西医院）,山西医科大学第三医院肿瘤中心胸部肿瘤科 华中科技大学同济医学院附属同济医院肿瘤中心
- 出处 《中国肿瘤临床》 CAS CSCD 北大核心 2022年第12期595-606,共12页
- 基金 国家重点研发计划项目(编号:2018YFC1313400) 国家自然科学基金项目(编号:81872166,U20A20375)资助。
- 摘要 目的:本研究的目的是建立基于临床和血液学参数的免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗的恶性肿瘤患者的免疫相关不良事件(immune-related adverse effects,irAEs)预测模型,如果经过验证,这些标记物的优点是易于整合到临床使用中,成本低廉。方法:本研究是对2016年1月到2020年12月在天津医科大学肿瘤医院和山西白求恩医院接受至少一剂ICIs治疗的恶性肿瘤患者的回顾性研究。收集了基线特征、治疗细节和不良事件的数据。采用t检验、χ2检验和Logistic回归等方法确定影响因素,建立预测模型。结果:任何级别和3级及以上的irAEs发生率分别为16.03%(76/474)和2.32%(11/474),其中最常见的分别为内分泌毒性37.1%(39/105)和肺炎7.6%(8/105)。多因素分析显示,2线治疗irAEs发生的风险更大[比值比(Odds Ratio,OR)=3.302];球蛋白(OR=1.086)与irAEs的发生呈正相关,而直接胆红素(direct bilirubin,DBIL)(OR=0.723)与其呈负相关(P<0.05)。最终建立了基于“ICIs类型、治疗线数、球蛋白、DBIL和淋巴细胞/单核细胞比值(lymphocyte to monocyte ratio,LMR)”的预测模型,其受试者工作特征(receiver operating characteristic,ROC)曲线下面积(area under the curve,AUC)为0.775,95%CI:0.711~0.840,P<0.05,临界值为0.118,敏感度为92.5%,特异度为56.6%。结论:基于ICIs类型、治疗线数、球蛋白、DBIL和LMR的预测模型对单纯接受ICIs的恶性肿瘤患者的irAEs预测效果较好,其中治疗线数、球蛋白和DBIL是irAEs发生的独立预测因素。ICIs作为2线治疗以及治疗前高球蛋白和低DBIL的人群发生ir-AEs的风险较高。
- 关键词 免疫检查点抑制剂 免疫相关不良事件 标志物 预测模型
- Keywords immune checkpoint inhibitors(ICIs) immune-related adverse events(irAEs) markers prediction model
- 分类号 R730.5 [医药卫生—肿瘤]
- 题名International guidelines on the diagnosis and treatment of NUT carcinoma 认领 引用 被引量：2
- 5
- 作者 Yu Zhang Qi Zhang Yue Hao Jia Luo Yingshi Piao Wenxian Wang Zhengbo Song Ziming Li Luka Brcic Aijun Liu Jinpu Yu Yasuhiro Tsutani Wenzhao Zhong Wenfeng Fang Zhijie Wang Shengxiang Ren Athanasios G.Papavassiliou Yongchang Zhang Jingjing Liu Shirong Zhang Xiuyu Cai Ayten Kayi Cangir Anwen Liu Wen Li Filippo Lococo Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Helmut Popper Yu Chen Jingping Yuan Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Kalevi Kairemo Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Ashrafian Leanne Xiaoyan Li Chuanhao Tang Hifzur R.Siddique Chengzhi Zhou Junping Zhang Junli Xue Vishal Shelat Hui Guo Qian Chu Rui Meng Fatemeh Ardeshir Jingxun Wu Rui Zhang Jin Zhou Robert A.Kratzke Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Fiorella Calabrese Yang Xia Alessandro Wasum Mariani Yuanyuan Lu Xiaofeng Chen Mark A.Klein Rui Ge Enyong Dai Axel H.Schönthal Yu Han Zhenying Guo Jian Zhang Yinghua Ji Xianbin Liang Hongmei Zhang Xuelei Ma Marco Chiappetta Xuewen Liu Francoise Galateau Salle Yu Yao Malgorzata Szolkowska Weiwei Pan Fei Pang Fan Wu Stefan B.Watzka Liping Wang Youcai Zhu Li Lin Aparna Sharma Jianfei Tu Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Marjorie G.Zauderer Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Elizabeth Dudnik Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Jianhui Huang Yue Feng Yinbin Zhang Binbin Song Wenfeng Li Jianfei Fu Marina K.Baine Pingli Sun Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Jing Wu Yunyun Yang Yuan Fang Zhen Wang Bin Wan Donglai Lv Huafei Chen Shengjie Yang Jing Kang Jiatao Zhang Chao Zhang Lin Shi Yina Wang Mohamed Emam Sobeih Bihui Li Bin Lian Lili Mao Zhang Zhang Ke Wang Zhongwu Li Zhefeng Liu Nong Yang Lin Wu Xiaobing Chen Gu Jin Miao Li Guansong Wang Thomas U.Marron Jiandong Wang Sanjay Popat Meiyu Fang Yong Fang Daniel Mansilla Yuan Li Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Aaron S.Mansfield Biyun Wang Lu Si Anja C.Roden Bjørn H.Grønberg Yong Song Geoffrey I.Shapiro Christopher A.French Yuanzhi Lu Qian Wang Chunwei Xu
- 机构 Department of Oncology,NHC Key Laboratory of Pulmonary Immune-related Diseases,Guizhou Provincial People's Hospital Department of Chemotherapy,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Lowe Center for Thoracic Oncology,Dana-Farber Cancer Institute,Brigham and Women's Hospital Department of Pathology,Beijing Tongren Hospital,Capital Medical University Department of Shanghai Lung Cancer Center,Shanghai Chest Hospital,Shanghai Jiao Tong University Department of Pathology,Hospital Graz II,Graz and Department of Pathology,Medical University of Vienna,1090 Vienna Senior Department of Pathology,The 7^（th）Medical Center of PLA General Hospital Department of Cancer Molecular Diagnostics Core,Tianjin Medical University Cancer Institute and Hospital Division of Thoracic Surgery,Department of Surgery,Kindai University Faculty of Medicine Guangdong Lung Cancer Institute,Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,School of Medicine Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine State Key Laboratory of Molecular Oncology,Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Department of Medical Oncology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University Department of Biological Chemistry,National and Kapodistrian University of Athens,11527 Athens Department of Medical Oncology,Lung Cancer and Gastrointestinal Unit,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Thoracic Cancer,Jilin Cancer Hospital Translational Medicine Research Center,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou First People's Hospital,Cancer Center,West Lake University School of Medicine Department of VIP Inpatient,Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine Department of Thoracic Surgery,Ankara University School of Medicine,Sihhiye Department of Oncology,Second Affiliated Hospital of Nanchang University Key Laboratory of Respiratory Disease of Zhejiang Province,Department of Respiratory and Critical Care Medicine,Second Affiliated Hospital of Zhejiang University School of Medicine,Cancer Center,Zhejiang University Unit of Thoracic Surgery,Fondazione Policlinico Gemelli IRCCS,00168 Rome Department of Respiratory Medicine,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Affiliated Drum Tower Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Clinical Medical School of Yangzhou University,Subei People's Hospital of Jiangsu Province Diagnostic and Research Institute of Pathology,Medical University of Graz,8010 Graz Department of Medical Oncology,Fujian Medical University Cancer Hospital&Fujian Cancer Hospital Department of Pathology,Renmin Hospital of Wuhan University Department of Internal Medicine,Cancer Center of PLA,Qinhuai Medical Area,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Integrative Oncology,Tianjin Medical University Cancer Institute and Hospital Department of Medical Oncology,Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Nuclear Medicine,University of Texas MD Anderson Cancer Center,Houston Department of Orthopaedic Oncology Surgery,Beijing Ji Shui Tan Hospital,Peking University Department of Radiotherapy and Chemotherapy,Hwamei Hospital,University of Chinese Academy of Sciences Department of Pulmonary Medicine,Taizhou Hospital of Wenzhou Medical University Department of Respiratory Medicine,the 900^（th）Hospital of the Joint Logistics Team（the Former Fuzhou General Hospital）,Fujian Medical University Department of Thoracic Surgery,Guy's Hospital,London SE19RT Department of Oncology,Beijing Tiantan Hospital,Capital Medical University Department of Medical Oncology,Peking University International Hospital Molecular Cancer Genetics&Translational Research Lab,Section of Genetics,Department of Zoology,Aligarh Muslim University State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University（The First Affiliated Hospital of Guangzhou Medical University） Department of Thoracic Oncology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital Department of Oncology,Shanghai East Hospital,School of Medicine,Tongji University Department of General Surgery,Tan Tock Seng Hospital Department of Oncology,the Second Affiliated Hospital of Medical College,Xi'an Jiaotong University Department of Oncology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology Emory Winship Cancer Institute,Atlanta Department of Medical Oncology,the First Affiliated Hospital of Medicine,Xiamen University Department of Medical Oncology,Cancer Hospital of China Medical University Department of Medical Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology Department of Medicine,University of Minnesota,Minneapolis Division of Heme-Onc-Transplant,420 Delaware St.SE,Minneapolis Department of Radiation Oncology,Fudan University Shanghai Cancer Center Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Radiation Oncology,Peking University Cancer Hospital&Institute Department of Cardiac,Thoracic,Vascular Sciences and Public Health.University of Padova,35128 Padova Department of Thoracic Surgery,Dante Pazzanese Institute of Cardiology,University of São Paulo School of Medicine State Key Laboratory of Cancer Biology,National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases,Fourth Military Medical University Department of Oncology,Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital Hematology/Oncology Section,Primary Care Service Line,Minneapolis VA Health Care System,Minneapolis Division of Hematology,Oncology and Transplantation,Department of Medicine,University of Minnesota,Minneapolis Department of General Surgery,Huadong Hospital Affiliated to Fudan University Department of Oncology and Hematology,China-Japan Union Hospital of Jilin University Department of Molecular Microbiology and Immunology,Keck School of Medicine,University of Southern California,Los Angeles Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital Department of Pathology,Zhejiang Provincial People's Hospital,Affiliated People's Hospital,Hangzhou Medical College Department of Oncology,Zhujiang Hospital,Southern Medical University Department of Oncology,The First Affiliated Hospital of Xinxiang Medical University Department of Oncology,The Third People's Hospital of Zhengzhou Department of Oncology,Xijing Hospital,Fourth Military Medical University Department of Biotherapy,State Key Laboratory of Biotherapy,Cancer Center,West China Hospital,Sichuan University Thoracic Surgery,Magna Graecia University,88100 Catanzaro Department of Oncology,the Third Xiangya Hospital,Central South University MESOPATH in the Department of Biopathology Cancer Center Leon Berard in Lyon,69373 Lyon Department of Medical Oncology,The First Affiliated Hospital of Xi'an Jiaotong University Department of Pathology,Institute of Tuberculosis and Lung Diseases,01-138 Warsaw Department of Cell Biology,College of Medicine,Jiaxing University Department of Medical,Shanghai OrigiMed Co. Department of Medical,Menarini Silicon Biosystems Spa Division of Thoracic Surgery,Karl Landsteiner Institute for Clinical and Translational Thoracic Surgical Research,Vienna Healthcare Group,Clinic Floridsdorf,1210 Vienna Department of Oncology,Baotou Cancer Hospital Department of Thoracic Disease Diagnosis and Treatment Center,Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University Department of Medical Oncology,Dr.B.R.A.IRCH,All India Institute of Medical Sciences Department of Oncology,Lishui Municipal Central Hospital Department of Interventional Pulmonary Diseases,Anhui Chest Hospital Department of Medical Oncology,Qilu Hospital,Cheeloo College of Medicine,Shandong University Department of Medical Oncology,Shanghai Changzheng Hospital,Naval Medical University Department of Oncology,Shandong Provincial Third Hospital,Cheeloo College of Medicine,Shandong University Division of Hematology&Medical Oncology,Department of Medicine,Westchester Medical Center,New York Department of Medicine,New York Medical College,New York Department of the Comprehensive Cancer Center,Affiliated Drum Tower Hospital,Medical School of Nanjing University Department of Pathology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital Department of Oncology,The First Affiliated Hospital of Anhui Medical University Department of Interventional Oncology,The First Affiliated Hospital,Sun Yat-sen University Ben Gurion University,Lung Cancer Service,Assuta Medical Centers Department of Respiratory Medicine,Huzhou Hospital,Zhejiang University School of Medicine Department of Gynecologic Radiation Oncology,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Department of Medical Oncology,The Affiliated Hospital of Jiaxing University Department of Radiation Oncology,First Affiliated Hospital of Wenzhou Medical College Department of Medical Oncology,Affiliated Jinhua Hospital,Zhejiang University School of Medicine Department of Pathology and Laboratory Medicine,Memorial Sloan Kettering Cancer Center,New York Department of Pathology,The Second Hospital of Jilin University Senior Department of Oncology,The 5^（th）Medical Center of PLA General Hospital Department of Pathology,Anhhui Provincial Children's Hospital Department of Radiation Oncology,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,The Affiliated Jiangning Hospital of Nanjing Medical University Department of Clinical Oncology,the 901 Hospital of Joint Logistics Support Force of People Liberation Army Department of Thoracic Surgery,Chuxiong Yi Autonomous Prefecture People's Hospital Department of Respiratory Medicine,Zhongshan Hospital,Fudan University Department of Oncology,The First Affiliated Hospital,College of Medicine,Zhejiang University Oncology,National Cancer Institute,Cairo University Department of Oncology,The Second Affiliated Hospital of Guilin Medical University Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Melanoma and Sarcoma,Peking University Cancer Hospital&Institute International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education（MOE）,Guangzhou City Key Laboratory of Precision Chemical Drug Development,School of Pharmacy,Jinan University National Health Commission（NHC）Key Laboratory of Nuclear Medicine,Jiangsu Key Laboratory of Molecular Nuclear Medicine,Jiangsu Institute of Nuclear Medicine Department of Radiopharmaceuticals,School of Pharmacy,Nanjing Medical University Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Pathology,Peking University Cancer Hospital&Institute Department of Internal Medicine,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital Department of Bone and Soft-tissue Surgery,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Department of Oncology,The Cancer Hospital of Qinghai Province Institute of Respiratory Diseases,Xinqiao Hospital,Third Military Medical University Early Phase Trials Unit,The Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,New York Department of Pathology,Affiliated Jinling Hospital,Medical School of Nanjing University Lung Unit,Royal Marsden Hospital,London SW36JJ Department of Medical Oncology,Sir Run Run Shaw Hospital,Zhejiang University Roffo Oncology Institute of Buenos Aires,Buenos Aires C1121AAR Department of Pathology,Fudan University Shanghai Cancer Center Department of Thoracic Surgery,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Oncology,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou Cancer Hospital,Cancer Center,Zhejiang University School of Medicine Department of Oncology,Mayo Clinic,Rochester Department of Breast Cancer and Urological Medical Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University Department of Laboratory Medicine and Pathology,Mayo Clinic,Rochester Department of Clinical and Molecular Medicine,Norwegian University of Science and Technology,7030 Trondheim Department of Oncology,St.Olav's Hospital,Trondheim University Hospital,7030 Trondheim Department of Medical Oncology,Dana-Farber Cancer Institute Department of Medicine Center for DNA Damage and Repair,Dana-Farber Cancer Institute Department of Pathology,Brigham and Women's Hospital Department of Pathology,the First Affiliated Hospital of Jinan University Department of Respiratory Medicine,Affiliated Hospital of Nanjing University of Chinese Medicine,Jiangsu Province Hospital of Chinese Medicine Hangzhou Institute of Medicine（HIM）,Chinese Academy of Sciences
- 出处 《The Innovation》 EI 2026年第1期111-126,共16页
- 基金 supported by the China Postdoctoral Science Foundation(grant number 2022M723207) the Medical Scientific Research Foundation of Zhejiang Province,China(grant number 2023KY666) +8 种基金 Zhejiang Traditional Chinese Medicine Science Fund Project(grant number 2024ZL372) Qiantang Cross Fund Project(grant number 2023-16) the National Natural Science Foundation of China of Zhejiang Cancer Hospital Cultivation Project(grant number PY2023006) the Medical Scientific Research Foundation of Zhejiang Province,China(grant number 2024KY812) the Natural Science Foundation of Zhejiang Province(grant number Q24H160110) the National Natural Science Foundation of China(grant number NSFC82371851) the Science and Technology Foundation of Guizhou Province(Outstanding Young Scientists of Guizhou Province)(grant number Qiankeherencai-YQK(2023)021) the Science and Technology Foundation of Guizhou Province(grant number Qiankehejichu-ZK(2023)General 212) the Science and Technology Foundation of Guizhou Province(grant number Qiankehechengguo-LC(2025)General 068).
- 摘要 1(NUTM1)gene rearrangements(15q14).In 1991,two independent research teams reported NC cases characterized by the t(15;19)translo-cation.1,2 In vitro studies by French et al.3 led to the pivotal discovery of NC in 2003 as a distinct disease entity driven by the fusion of bromodo-main and extraterminal domain(BET)protein 4(BRD4)and NUTM1.In 2004,the World Health Organization(WHO)classified tumors with t(15;19)translocation as a thymic malignancy and designated it“NUT midline carcinoma,”due to its predominant occurrence in midline organs.4 However,subsequent reports revealed NC’s emergence in numerous nonmidline organs,leading to its reclassification as the independent entity“NUT carcinoma of the thorax”by the WHO in 2015.5 NC exhibits rapid progression and profound resistance to conventional radiotherapy and chemotherapy.
- 关键词 t BRD vitro studies translocation nut carcinoma thorax thymic malignancy nut midline carcinoma NUTM
- 分类号 R730.5 [医药卫生—肿瘤]
-
- 题名Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations 认领 引用 被引量：6
- 6
- 作者 Wenxian Wang Bin Lian Chunwei Xu Qian Wang Ziming Li Nan Zheng Aijun Liu Jinpu Yu Wenzhao Zhong Zhijie Wang Yongchang Zhang Jingjing Liu Shirong Zhang Xiuyu Cai Anwen Liu Wen Li Lili Mao Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Yu Chen Jingping Yuan Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Xiaoyan Li Chuanhao Tang Chengzhi Zhou Junping Zhang Junli Xue Hui Guo Qian Chu Rui Meng Xuewen Liu Jingxun Wu Rui Zhang Jin Zhou Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Yuanyuan Lu Xiaofeng Chen Jian Feng Rui Ge Enyong Dai Yu Han Weiwei Pan Fei Pang Xin Huang Meizhen Hu Qing Hao Kai Wang Fan Wu Binbin Song Bingwei Xu Liping Wang Youcai Zhu Li Lin Yanru Xie Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Jianhui Huang Yue Feng Yinbin Zhang Pingli Sun Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Yue Hao Zhen Wang Bin Wan Donglai Lv Shengjie Yang Jin Kang Jiatao Zhang Chao Zhang Wenfeng Li Jianfei Fu Lizhi Wu Shijie Lan Juanjuan Ou Lin Shi Zhanqiang Zhai Yina Wang Bihui Li Zhang Zhang Ke Wang Xuelei Ma Zhongwu Li Zhefeng Liu Nong Yang Lin Wu Huijuan Wang Gu Jin Guansong Wang Jiandong Wang Hubing Shi Meiyu Fang Yong Fang Yuan Li Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Biyun Wang Yong Song Zhengbo Song Wenfeng Fang Yuanzhi Lu Lu Si
- 机构 Department of Chemotherapy,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Melanoma and Sarcoma,Peking University Cancer Hospital&Institute Institute of Cancer and Basic Medicine（ICBM）,Chinese Academy of Sciences Department of Respiratory Medicine,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Affiliated Hospital of Nanjing University of Chinese Medicine,Jiangsu Province Hospital of Chinese Medicine Department of Shanghai Lung Cancer Center,Shanghai Chest Hospital,Shanghai Jiao Tong University Beijing Key Laboratory of Mental Disorders,National Clinical Research Center for Mental Disorders&National Center for Mental Disorders,Beijing Anding Hospital,Capital Medical University Advanced Innovation Center for Human Brain Protection,Capital Medical University Senior Department of Pathology,the 7th Medical Center of PLA General Hospital Department of Cancer Molecular Diagnostics Core,Tianjin Medical University Cancer Institute and Hospital Guangdong Lung Cancer Institute,Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,School of Medicine State Key Laboratory of Molecular Oncology,Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Department of Medical Oncology,Lung Cancer and Gastrointestinal Unit,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Thoracic Cancer,Jilin Cancer Hospital Translational Medicine Research Center,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou First People’s Hospital,Cancer Center,West Lake University School of Medicine Department of VIP Inpatient,Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine Department of Oncology,Second Affiliated Hospital of Nanchang University,Nanchang Key Laboratory of Respiratory Disease of Zhejiang Province,Department of Respiratory and Critical Care Medicine,Second Affiliated Hospital of Zhejiang University School of Medicine,Cancer Center,Zhejiang University Department of Respiratory Medicine,Affiliated Drum Tower Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Clinical Medical School of Yangzhou University,Subei People’s Hospital of Jiangsu Province,Yangzhou Department of Medical Oncology,Fujian Medical University Cancer Hospital&Fujian Cancer Hospital Department of Pathology,Renmin Hospital of Wuhan University Department of Internal Medicine,Cancer Center of PLA,Qinhuai Medical Area,Affiliated Jinling Hospital,Medical School of Nanjing University Derpartment of Integrative Oncology,Tianjin Medical University Cancer Institute and Hospital Department of Medical Oncology,Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Orthopaedic Oncology Surgery,Beijing Ji Shui Tan Hospital,Peking University Department of Radiotherapy and Chemotherapy,Hwamei Hospital,University of Chinese Academy of Sciences Department of Pulmonary Medicine,Taizhou Hospital of Wenzhou Medical University,Taizhou Department of Respiratory Medicine,the 900th Hospital of the Joint Logistics Team（the Former Fuzhou General Hospital）,Fujian Medical University Department of Oncology,Beijing Tiantan Hospital,Capital Medical University Department of Medical Oncology,Peking University International Hospital State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University Department of Thoracic Oncology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital,Taiyuan Department of Oncology,Shanghai East Hospital,School of Medicine,Tongji University Department of Medical Oncology,The First Affiliated Hospital of Xi’an Jiaotong University Department of Oncology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology Department of Oncology,the Third Xiangya Hospital,Central South University Department of Medical Oncology,the First Affiliated Hospital of Medicine,Xiamen University Department of Medical Oncology,Cancer Hospital of China Medical University,Shenyang Department of Medical Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology Department of Radiation Oncology,Fudan University Shanghai Cancer Center Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Radiation Oncology,Peking University Cancer Hospital&Institute State Key Laboratory of Cancer Biology,National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases,Fourth Military Medical University Department of Oncology,Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital Department of Respiratory Medicine,Affiliated Hospital of Nantong University,Nantong Department of General Surgery,Huadong Hospital Affiliated to Fudan University Department of Oncology and Hematology,China-Japan Union Hospital of Jilin University,Changchun Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital Department of Cell Biology,College of Medicine,Jiaxing University,Jiaxing Department of Medical,Shanghai OrigiMed Co. Department of Medical,Menarini Silicon Biosystems Spa Department of Medical Oncology,The Affiliated Hospital of Jiaxing University,Jiaxing Department of Biotherapy,Cancer Institute,First Affiliated Hospital of China Medical University Department of Oncology,Baotou Cancer Hospital Department of Thoracic Disease Diagnosis and Treatment Center,Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University,Jiaxing Department of Oncology,Lishui Municipal Central Hospital Department of Interventional Pulmonary Diseases,Anhui Chest Hospital Department of Medical Oncology,Qilu Hospital,Cheeloo College of Medicine,Shandong University Department of Medical Oncology,Shanghai Changzheng Hospital,Naval Medical University Department of Oncology,Shandong Provincial Third Hospital,Cheeloo College of Medicine,Shandong University Department of the Comprehensive Cancer Center,Affiliated Drum Tower Hospital,Medical School of Nanjing University Department of Pathology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital,Taiyuan Department of Oncology,The First Affiliated Hospital of Anhui Medical University Department of Interventional Oncology,The First Affiliated Hospital,Sun Yat-sen University Department of Respiratory Medicine,Huzhou Hospital,Zhejiang University School of Medicine Department of Gynecologic Radiation Oncology,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Department of Oncology,the Second Affiliated Hospital of Medical College,Xi’an Jiaotong University Department of Pathology,The Second Hospital of Jilin University,Changchun Senior Department of Oncology,The 5th Medical Center of PLA General Hospital Department of Radiation Oncology,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,The Affiliated Jiangning Hospital of Nanjing Medical University Department of Clinical Oncology,The 901 Hospital of Joint Logistics Support Force of People Liberation Army Department of Thoracic Surgery,Chuxiong Yi Autonomous Prefecture People’s Hospital,Chuxiong Department of Radiation Oncology,First Affiliated Hospital of Wenzhou Medical College,Wenzhou Department of Medical Oncology,Affiliated Jinhua Hospital,Zhejiang University School of Medicine Department of Microsurgery,Taizhou Hospital Affiliated to Wenzhou Medical University,Taizhou Department of Cancer Center,The First Hospital of Jilin University,Changchun Department of Oncology and Southwest Cancer Center,Southwest Hospital,Third Military Medical University（Army Medical University） Department of Respiratory Medicine,Zhongshan Hospital,Fudan University Department of Oncology,The First Affiliated Hospital,College of Medicine,Zhejiang University Department of Oncology,The Second Affiliated Hospital of Guilin Medical University International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education（MOE）,Guangzhou City Key Laboratory of Precision Chemical Drug Development,School of Pharmacy,Jinan University National Health Commission（NHC）Key Laboratory of Nuclear Medicine,Jiangsu Key Laboratory of Molecular Nuclear Medicine,Jiangsu Institute of Nuclear Medicine Department of Radiopharmaceuticals,School of Pharmacy,Nanjing Medical University Department of Biotherapy,State Key Laboratory of Biotherapy,Cancer Center,West China Hospital,Sichuan University Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Pathology,Peking University Cancer Hospital&Institute Department of Internal Medicine,The Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital Department of Bone and Soft-tissue Surgery,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Institute of Respiratory Diseases,Xinqiao Hospital,Third Military Medical University Department of Pathology,Affiliated Jinling Hospital,Medical School of Nanjing University Frontier Science Center for Disease Molecular Network,West China Hospital,Sichuan University Department of Medical Oncology,Sir Run Run Shaw Hospital,Zhejiang University Department of Pathology,Fudan University Shanghai Cancer Center Department of Thoracic Surgery,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Oncology,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou Cancer Hospital,Cancer Center,Zhejiang University School of Medicine Department of Breast Cancer and Urological Medical Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine Department of Clinical Pathology,The First Affiliated Hospital of Jinan University
- 出处 《The Innovation》 EI 2024年第6期100-116,共17页
- 基金 supported by the Natural Science Foundation of China(grant number 82002456) China Postdoctoral Science Foundation(grant number 2022M723207) +10 种基金 the Medical Scientific Research Foundation of Zhejiang Province,China(grant number 2023KY666) Zhejiang Traditional Chinese Medicine Science Fund Project(grant number 2024ZL372) Qiantang Cross Fund Project(grant number 2023-16) National Natural Science Foundation of China of Zhejiang Cancer Hospital Cultivation Project(grant number PY2023006) the Medical Scientific Research Foundation of Zhejiang Province,China(grant number 2024KY812) the Natural Science Foundation of Zhejiang Province(grant number LQ24H160036) Beijing Health Technologies Promotion Program[grant number BHTPP2022041] Peking University Clinical Scientist Training Program and the Fundamental Research Funds for the Central Universities[grant number BMU2024PYJH010] Science Foundation of Peking University Cancer Hospital[grant number PY202333] the Beijing Natural Science Foundation[grant number 7232248] Beijing Hospitals Authority Youth Programme[grant number QML20231902].
- 摘要 The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and survival.When the BRAF gene mutates,it can lead to abnormal activation of the signaling pathway,which promotes cell proliferation,inhibits cell apoptosis,and ultimately contributes to the occurrence and development of cancer.BRAF mutations are widely present in various cancers,including malignant melanoma,thyroid cancer,colorectal cancer,non-small cell lung cancer,and hairy cell leukemia,among others.BRAF is an important target for the treatment of various solid tumors,and targeted combination therapies,represented by BRAF inhibitors,have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors.
- 关键词 BRAF diagnosis treatment
- 分类号 R730.5 [医药卫生—肿瘤]
-
